Breast Cancer

Docetaxel (Taxotere) and vinorelbine (Navelbine) are active agents in the treatment of metastatic breast cancer. Preclinical data suggest that there may be synergism between vinca alkaloids and taxane compounds. The current study evaluates the combination of docetaxel and vinorelbine with concurrent granulocyte colony-stimulating factor (G-CSF, filgrastim [Neupogen]) in anthracycline-refractory breast cancer. The objectives of this study are to determine the response rate, time to progression, survival, and toxicities of this regimen.

Weekly administration of taxanes as palliative treatment in metastatic breast cancer has been reported with significantly reduced hematologic toxicity and comparable efficacy to standard every-3-week protocols. This study update provides mature results with weekly docetaxel (Taxotere) in a larger patient population.

Increasing the dose density of active drugs by delivering maximum tolerated doses sequentially with minimal intervals between cycles could potentially increase response rate and benefit in metastatic breast cancer. We tested this hypothesis by assigning

Based on results from phase I studies, one of the recommended doses for doxorubicin/docetaxel (Taxotere) is doxorubicin 60 mg/m² plus docetaxel 60 mg/m² every 21 days. However, information on the efficacy and toxicity of this dose level in

Docetaxel (Taxotere) is a semisynthetic taxane that has efficacy in combination regimens with doxorubicin (Adriamycin) in the treatment of metastatic breast cancer. This study was instituted to assess the role of this combination in the neoadjuvant treatment of locally advanced breast cancer (LABC).

From March 1996 to March 1998, 106 patients with untreated metastatic breast cancer (MBC) were treated with docetaxel (Taxotere) (100 mg/m²) and doxorubicin (75 mg/m²) on an alternating cycle-by-cycle (doxorubicin, docetaxel, doxorubicin, etc) or sequential (four cycles of docetaxel, then four cycles of doxorubicin) basis, every 3 weeks, for a maximum of eight cycles.

Results of the GEPARDO Trial: A Phase IIB Study Comparing the Combination of Dose-Intensified Doxorubicin and Docetaxel With or Without Tamoxifen in Patients With Operable Breast Cancer

MIAMI, Florida-Results of a recent study suggest that Herceptin (trastuzumab) may be effective as single-agent therapy in chemotherapy-naïve women with metastatic breast cancer, said lead investigator Charles Vogel, MD, clinical professor of medicine, University of Miami School of Medicine.

PITTSBURGH-Four cycles of doxorubicin (Adriamycin) and cyclophosphamide (AC) over 63 days are as effective as six cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) over 6 months in node-negative, early- stage breast cancer, Bernard Fisher, MD, reported at the ASCO annual meeting.

NEW ORLEANS-In a phase II study, combined treatment with Herceptin (trastuzumab) and vinorelbine (Navelbine) improved response rates and survival in women with HER2-positive metastatic breast cancer.

NEW YORK-“Survival rates could be improved if all women understood the benefits of early detection and could utilize high-quality breast cancer screening services in their communities, regardless of their ability to pay,” said Wanda K. Jones, DrPh, leadoff speaker at the National Alliance of Breast Cancer Organizations’ (NABCO) Celebration 2000 fund-raising luncheon.

This book is the 17th volume in the Basic and Clinical Oncology series edited by Bruce D. Cheson, MD. Like other volumes in this series, Expert Consultations in Breast Cancer follows a unique format and seeks to integrate advances in the basic understanding of breast cancer with promising new therapies and changing health- care economics. The integration of these different perspectives provides both a conceptual and pragmatic framework for clinical decision-making.

The results of a multicenter, phase III metastatic breast cancer study indicates that, in women with previously untreated metastatic breast cancer, sequential chemotherapy induction using doxorubicin and docetaxel (Taxotere) is as effective and

NEW ORLEANS-Epirubicin (Ellence) may be an effective single agent for primary treatment of operable breast cancer, according to results of a cooperative group study from the National Tumor Institute, Milan, Italy, presented at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).

NEW ORLEANS-A pilot study of ultrasound-guided percutaneous radio-frequency ablation (RFA) in patients with early-stage breast cancer suggests that the technique might someday be an alternative to surgical resection in carefully selected patients.

STUTTGART, Germany-Mitoxantrone (Novantrone) alone gives high-risk metastatic breast cancer patients a better quality of life than a combination of fluorouracil, epirubicin, and cyclophosphamide (FEC), according to results presented at the 36th Annual Meeting of the American Society of Clinical Oncology. Yet the single agent appears to work as well as combination therapy when compared for several endpoints.

NEW YORK-Dramatic advances in the treatment, detection, and prevention of breast cancer are occurring because of research efforts of the past 30 years, experts emphasized at the International Roundtable on Breast Cancer: Today’s Choices, Tomorrow’s Chances for a Cure, sponsored by the American-Italian Cancer Foundation and the Susan G. Komen Breast Cancer Foundation.

MUNICH-The presence of bone marrow micrometastases in breast cancer patients, as determined by detection of cytokeratin-positive cells, predicts a poor prognosis regardless of lymph node status, according to a German study.

Data presented at the annual meeting of the American Society of Clinical Oncology further validated ChromaVision Medical Systems’ automated cellular imaging system (ACIS). The data from a collaborative study conducted by the United States National Institutes of Health, the Institute of Pathology in Basel, Switzerland, and two diagnostic companies, DAKO A/S and Vysis, Inc, documented that results of the ACIS HER2 immunohistochemical test correlate strongly with overall patient survival. Tests that provide information to help predict both the time and likelihood of survival are vital to clinicians in guiding critical treatment decisions.

NEW ORLEANS-Preliminary results of National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21 have ended the “lingering, perhaps illusory hope of identifying a subset of women in whom radiation could be eliminated or replaced with another intervention” for treating early-stage invasive breast cancer, said Norman Wolmark, MD, chairman of the NSABP.

ASCO-Breast cancer patients receiving care in hospitals that treat fewer than 25 patients a year have substantially lower survival rates than women treated in larger-volume hospitals, according to a study presented at a poster session of the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO), New Orleans.

HOUSTON-A study comparing eight cycles of adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) to four cycles of paclitaxel (Taxol) followed by four cycles of FAC in women with operable breast cancer showed a nonsignificant trend toward benefit from the paclitaxel/FAC regimen.

NEW YORK-A new regimen of weekly paclitaxel (Taxol) plus the monoclonal antibody trastuzumab (Herceptin) produced an overall response rate of 60% among metastatic breast cancer patients, regardless of HER2 status, according to a study presented at the ASCO meeting.

TOULOUSE, France-Accrual problems continue to plague clinical trials, most recently a French study attempting to compare complete hormonal blockade with luteinizing hormone–releasing hormone (LHRH) to chemotherapy in premenopausal early-stage breast cancer. Patients in the study were hormone-receptor positive and had one to three positive lymph nodes.

BETHESDA, Md-Despite bad press and negative scientific findings to date, the National Cancer Institute has not written off high-dose chemotherapy with bone marrow or stem cell transplant as a treatment for breast cancer. Indeed, NCI director Richard D. Klausner, MD, has publicly appealed to oncologists to support a major ongoing but faltering NCI-sponsored breast cancer transplant trial.